MRI dye may shield cancer patients from nerve pain
NCT ID NCT00727922
First seen Nov 20, 2025 · Last updated May 23, 2026 · Updated 18 times
Summary
This study tested whether mangafodipir, an MRI contrast agent with antioxidant properties, could reduce nerve damage caused by the chemotherapy drug oxaliplatin. 23 cancer patients who already had moderate nerve problems took part. The goal was to see if mangafodipir could allow them to continue effective chemotherapy without worsening nerve symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cochin
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.